Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways
PHI inhibits inflammation and apoptosis in vitro and alleviates diabetic kidney injury in db/db mice by interfering TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. Thus, this study reveals for the first time that PHI is a potential novel therapeutic agent for DN.
Authors
- Junwei Xie (ORCID: https://orcid.org/0000-0002-4045-0538)
- Shaokang Pan (ORCID: https://orcid.org/0000-0001-6741-9496)
- Xiaoyue Yu (ORCID: https://orcid.org/0000-0002-7321-0303)
- Yixue Wang (ORCID: https://orcid.org/0000-0001-5254-5940)
- Fengxun Liu
- Shiyang Li (ORCID: https://orcid.org/0000-0003-2023-0949)
- Dongwei Liu (ORCID: https://orcid.org/0000-0002-0697-0548)
- Xiaonan Zhang (ORCID: https://orcid.org/0000-0003-0155-776X)
- Zhangsuo Liu (ORCID: https://orcid.org/0000-0002-8120-9767)
- Qi Feng (ORCID: https://orcid.org/0000-0001-6810-7363)
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1016/j.phymed.2024.156314
- Citations
- 20
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 6.78